BIOMAT Database Logo BIOMAT Database Logo

Clinical evaluation of selegiline (L-deprenyl) in the long-term L-dopa treatment syndrome. 1985

F Trebini, and D Daniele, and S Gillio, and L Scarzella

UI MeSH Term Description Entries
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D010627 Phenethylamines A group of compounds that are derivatives of beta- aminoethylbenzene which is structurally and pharmacologically related to amphetamine. (From Merck Index, 11th ed) Phenylethylamines
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

F Trebini, and D Daniele, and S Gillio, and L Scarzella
Selegiline (L-deprenyl) and L-dopa treatment of Parkinson's disease: a double-blind trial.
September 1994, Internal medicine (Tokyo, Japan),
F Trebini, and D Daniele, and S Gillio, and L Scarzella
Clinical evaluation of deprenyl (selegiline) in the treatment of Parkinson's disease.
January 1983, Acta neurologica Scandinavica. Supplementum,
F Trebini, and D Daniele, and S Gillio, and L Scarzella
Long term treatment with L-deprenyl.
January 1978, Journal of neural transmission,
F Trebini, and D Daniele, and S Gillio, and L Scarzella
Biochemical actions of l-deprenyl (selegiline).
December 1994, Clinical pharmacology and therapeutics,
F Trebini, and D Daniele, and S Gillio, and L Scarzella
[Long-term syndrome in the treatment of parkinsonism with L-dopa].
January 1975, Acta neurologica latinoamericana,
F Trebini, and D Daniele, and S Gillio, and L Scarzella
Marked improvement in Segawa syndrome after L-dopa and selegiline treatment.
May 2010, Pediatric neurology,
F Trebini, and D Daniele, and S Gillio, and L Scarzella
Evaluation of physical dependence liability of l-deprenyl (selegiline) in animals.
December 1994, Clinical pharmacology and therapeutics,
F Trebini, and D Daniele, and S Gillio, and L Scarzella
Effects of selegiline (L-deprenyl) during smoking and short-term abstinence.
September 2002, Psychopharmacology,
F Trebini, and D Daniele, and S Gillio, and L Scarzella
Long-term efficacy and safety of deprenyl (selegiline) in advanced Parkinson's disease.
August 1989, Neurology,
F Trebini, and D Daniele, and S Gillio, and L Scarzella
Postpolio syndrome--response to deprenyl (selegiline).
January 1993, The International journal of neuroscience,
Copied contents to your clipboard!